Search results
Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year
GuruFocus.com via Yahoo Finance· 5 months agoCuris Inc (NASDAQ:CRIS) reported a net loss of $12.2 million for Q3 2023, a decrease compared to...
Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoCuris, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript February 8, 2024 Curis, Inc. misses on...
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
Simply Wall St. via Yahoo Finance· 3 months agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
What Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares?
Simply Wall St. via Yahoo Finance· 2 years agoEvery investor in Curis, Inc. (NASDAQ:CRIS) should be aware of the most powerful shareholder groups....
Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth
Simply Wall St. via Yahoo Finance· 11 months agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount?
Simply Wall St. via Yahoo Finance· 10 months agoKey Insights Using the 2 Stage Free Cash Flow to Equity, Curis fair value estimate is US$1.58...
Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting
Benzinga via Yahoo Finance· 2 years agoCuris Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia...
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
Benzinga via Yahoo Finance· 2 years agoThe FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the...
Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this...
Simply Wall St. via Yahoo Finance· 2 years agoCuris, Inc. (NASDAQ:CRIS) shareholders should be happy to see the share price up 30% in the last...
Curis Plummets To 52-Week Low After FDA Clinical Hold On Blood Cancer Trial
Benzinga via Yahoo Finance· 2 years agoThe FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a...